aditXt (Nasdaq: ADTX)

aditXt (Nasdaq: ADTX) is delighted to welcome Sylvia Hermina to its Board of Directors. With over 20 years of experience advising public companies on corporate governance, mergers and acquisitions, and shareholder relations, Ms. Hermina brings a wealth of expertise in fostering effective and impactful engagement between management teams and stakeholders. Read the full release here: https://lnkd.in/dfsXHcHu #WomenInLeadership #WomenInHealth #InnovativeHealth

Join us on October 28, 2024, at 11:30 AM ET for a Virtual Fireside Chat with aditXt (Nasdaq: ADTX) CEO, Amro Albanna, and Evofem Biosciences CEO, Saundra Pelletier, moderated by MD & TV Personality Dr. Drew Pinsky. The session will cover key updates on aditXt’s acquisition of Evofem, plan post-acquisition, and a live Q&A. We encourage you to engage with our panel by submitting your questions via text or video to engagement@aditxt.com by October 25, 2024, at 5:00 PM ET. Register for the event here: https://lnkd.in/g8RfryVa Read more about the event: https://lnkd.in/g4Gh2kUv #WomensHealth #Innovation #Biotech #Healthcare #Endometriosis #Womensreproductivehealth #WomensReproductiveHealth #ReproductiveAutonomy

Join us for a stakeholder update and Q&A session this Friday. “Sessions like these allow us to share our progress, challenges, and the exciting potential of our programs with those who believe in our mission to accelerate promising health innovations.” Amro Albanna On Friday, October 11, 2024, at 11:30 AM EDT, we will be hosting a session with CEO Amro Albanna to keep our stakeholders informed and engaged with our latest developments. What’s on the agenda? - aditXt overview & transaction Updates: get the latest on our Evofem Biosciences and Appili Therapeutics transactions. - Program highlights: updates on our ongoing immune and precision health programs. - Year-end roadmap: discover our goals for the remainder of 2024. - Q&A with Amro Albanna: Addressing questions submitted by our stakeholders We believe in transparent communication and value every voice in our community. If you have questions you’d like answered, please submit them by Thursday, October 10, 2024, at 5:00 PM EDT to engagement@aditxt.com. Register today to secure your spot:  https://lnkd.in/d9yxx62b #StakeholderEngagement #HealthcareInnovation #Evofem #PublicHealth #WomenHealth #InvestorRelations #Nasdaq

Endometriosis, a painful condition affecting 190 million women worldwide, has long lacked effective and non-invasive diagnostic tools. Currently, no validated blood-based tests for endometriosis are available in the United States or anywhere around the world. Aditxt subsidiary Pearsanta, Inc.’s  Mitomic® Endometriosis Test (MET™) seeks to become the first and only validated and commercialized blood-based biomarker test for endometriosis. Pearsanta's MET looks for a specific deletion in mitochondrial DNA (“mtDNA”), a novel, proprietary biomarker for endometriosis. Today, we announced that Pearsanta, Inc. has entered into a Market Development Collaboration Agreement with Evofem Biosciences. Under the Agreement, Evofem and Pearsanta will collaborate to develop a comprehensive go-to-market strategy and MET commercial plan ahead of the planned U.S. launch in mid-2025. Read the full press release here: https://lnkd.in/dP7Q9PzW #Endometriosis #HealthcareInnovation #Diagnostics #WomensHealth #PrecisionMedicine #mtDNA

aditXt (Nasdaq ADTX) will present at the H.C. Wainwright & Co., LLC 26th annual global investment conference, September 9th-11th, 2024. Our corporate overview will be available on-demand starting Monday, September 9th, at 7:00 a.m. (ET) through the conference platform. In addition to the virtual presentation, Amro Albanna will be available for one-on-one meetings throughout the conference, providing in-depth insights into our innovative programs, proposed acquisitions, and strategic plans for 2025. https://lnkd.in/d23MUhqm #InvestmentConference #HealthcareInnovation #InvestmentOpportunities

We are delighted to announce the appointment of Chris Mitton as President of Pearsanta as we accelerate our efforts to transform precision health. Christopher brings over 20 years of leadership experience in the medical diagnostics industry, with a strong focus on personalized healthcare and molecular oncology. His expertise will be instrumental in advancing Pearsanta's Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™) through clinical validation studies and preparing for commercial launch. Read the full press release here - https://lnkd.in/ggFhTNKK #PrecisionHealth #Leadership #Innovation #Diagnostics #Pearsanta #Endometriosis #ProstateCancer #OvarianCancer #LiquidBiopsy

We are pleased to share that all proposals from our recent annual shareholders' meeting have been approved. These approvals cover essential decisions on board elections, share issuance, equity lines, and more, equipping us with the flexibility and resources to drive our strategic initiatives forward. Thank you to all our stakeholders for their participation and ongoing support. Read the full press release here: https://lnkd.in/dmZ5rxnT #Innovation #Nasdaq #Biotech #HealthcareInnovation #Immunehealth #PrecisionHealth #PublicHealth #WomensHealth

At aditXt (Nasdaq ADTX), our mission is to accelerate innovations with the potential to address the most pressing health challenges. According to the World Ovarian Cancer Coalition, ovarian cancer remains a significant health concern, with over 324,603 new cases diagnosed worldwide in 2022. It is the 18th most common cancer globally. And the 8th most common among women, according to the World Cancer Research Fund. The lifetime risk for a woman being diagnosed with ovarian cancer is approximately 1 in 87, while the risk of dying from invasive ovarian cancer is about 1 in 130, based on information provided by the American Cancer Society. According to the Ovarian Cancer Research Alliance the five-year relative survival rate for ovarian cancer stands at around 50.8%. Despite the prevalence of this cancer, we do not believe that any blood tests are currently available with adequate sensitivity for early detection of ovarian cancer, underscoring a critical need for improved diagnostic methods. The team at Pearsanta, Inc. has submitted a proposal for the Clinical Trial Translational Endpoints Research Award to the Congressionally Directed Medical Research Programs (CDMRP) of the United States Department of Defense. This proposal aims to validate a novel assay based on Pearsanta’s proprietary Mitomic® Technology for the early detection of ovarian cancer. Pearsanta’s proprietary Mitomic Technology Platform seeks to harness the unique properties of mitochondrial DNA (mtDNA) to detect disease through non-invasive, blood-based liquid biopsies. This platform is designed to identify specific mutations in mtDNA indicative of various diseases. Due to its high mutation rate and cell persistence, Pearsanta believes mtDNA is an excellent biomarker for early disease detection. This platform allows for the rapid and accurate identification of disease-associated biomarkers, significantly enhancing early diagnosis and treatment. Currently, the program focuses on developing tests for early cancer detection, targeting ovarian, prostate, and lung cancers, and addressing non-cancerous conditions like endometriosis. Read more here https://lnkd.in/d--eBTuD #WomensHealth #OvarianCancer #EarlyDetection #mtDNA #LiquidBiopsy #ClinicalResearch #CancerDiagnostics #HealthcareInnovation #ReproductiveHealth #RoevWade #RoevWadeMatters #ReproductiveRights #WomensRights #Endometriosis #ProstateCancer #Evofem Evofem Biosciences

Fantastic news Saundra Pelletier & all the Evofem Biosciences team.